These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19535798)

  • 1. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
    Stanulla M; Schaeffeler E; Möricke A; Coulthard SA; Cario G; Schrauder A; Kaatsch P; Dördelmann M; Welte K; Zimmermann M; Reiter A; Eichelbaum M; Riehm H; Schrappe M; Schwab M
    Blood; 2009 Aug; 114(7):1314-8. PubMed ID: 19535798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
    Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
    JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
    Tantawy AAG; Ebeid FSE; Adly AAM; El-Ghoroury E; Mostafa M
    J Genet; 2017 Dec; 96(6):905-910. PubMed ID: 29321348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
    Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
    McLeod HL; Krynetski EY; Relling MV; Evans WE
    Leukemia; 2000 Apr; 14(4):567-72. PubMed ID: 10764140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003.
    Lennard L; Cartwright CS; Wade R; Vora A
    Br J Haematol; 2015 Aug; 170(4):550-8. PubMed ID: 25940902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
    Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.
    Chrzanowska M; Kuehn M; Januszkiewicz-Lewandowska D; Kurzawski M; Droździk M
    Acta Pol Pharm; 2012; 69(3):405-10. PubMed ID: 22594254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
    Lennard L; Welch JC; Lilleyman JS
    Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
    Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
    Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
    Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
    Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
    Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
    Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.